Using a daily extended-release tablet of deucrictibant — an oral small molecule being developed by Pharvaris — together with deucrictibant in its immediate-release formulation as an on-demand treatment for acute attacks of hereditary angioedema (HAE) is expected to be safe based on computer data. A presentation on…
News
The experimental therapy navenibart was well tolerated and was associated with fewer swelling attacks and improved quality of life in adults with hereditary angioedema (HAE) when given every few months in an early clinical trial, a study showed. “The proof-of-concept data … suggest that infrequent administration of navenibart…
It wasn’t until nearly a decade after she first started experiencing symptoms that a woman in China was diagnosed with hereditary angioedema (HAE), despite a family history of swelling bouts and years of abdominal pain, as described in a new report. A routine blood test at age…
Treatment with Xolair (omalizumab), an approved therapy for allergic asthma and chronic spontaneous urticaria (CSU), was associated with strong symptom control in people with mast cell–mediated angioedema, according to a large real-world study. Benefits were observed regardless of whether patients experienced wheals, itchy skin bumps commonly known as…
On-demand treatment with Ekterly (sebetralstat), marketed by Kalvista Pharmaceuticals for hereditary angioedema (HAE), reduced anxiety associated with swelling attacks more quickly and effectively than a placebo in a recent study. “Moderate-to-extreme anxiety was common,” the researchers wrote, but it eased with treatment, particularly in patients who were…
Deucrictibant, an experimental oral small molecule from Pharvaris, delivers rapid relief when used on demand for acute attacks of hereditary angioedema (HAE) and can, over time, also reduce the frequency of the swelling that causes the attacks,…
Children as young as 2 years may soon have access to the first-ever oral treatment for sudden hereditary angioedema (HAE) attacks. New Phase 3 data from developer Kalvista Pharmaceuticals suggests that Ekterly (sebetralstat) is both safe and effective for young children, offering a needle-free alternative to the…
For people in Puerto Rico with hereditary angioedema (HAE), long-term treatment with Takhzyro (lanadelumab) is safe and effective for preventing swelling attacks, new real-world data show. Specifically, more than two years of treatment with the approved injection medication safely and effectively maintained low HAE attack rates among people of Hispanic or…
A woman in her 80s who had taken the same blood pressure medication for 11 years without issue suddenly developed a life-threatening reaction, marked by angioedema (swelling) in both her digestive tract and airway, a new case report reveals. The rare dual presentation initially mimicked a bowel obstruction, nearly…
A 56-year-old man’s recurring abdominal pain and bowel issues were finally traced back to a rare genetic condition, hereditary angioedema (HAE), according to a recent case report. Despite the patient’s age and lack of family history, genetic testing identified a mutation in the SERPING1 gene, and his symptoms were…
Recent Posts
- Combined use of deucrictibant formulations in HAE expected to be safe
- HAE attacks drop with infrequent navenibart dosing in early trial
- Case of woman in China shows impact of delayed diagnosis in HAE
- With HAE, minding your mental and emotional well-being requires self-care
- Many angioedema patients see relief with Xolair in new real-world study